EX-99.1 2 rcel-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 AVITA Medical Reports Second Quarter Results, Raises 2026 Revenue Guidance, and Expects Fourth Quarter Cash Flow Breakeven VALENCIA, Calif., August 6, 2026 (GLOBE NEWSWIRE) - AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions (“AVITA Medical,” or the “Company”), today reported financial results for the second quarter ended June 30, 2026. Second Quarter 2026 Financial Highlights • Q2 net revenue grew 18% year over year and 13% sequentially quarter-over-quarter to a record $21.7 million o Revenue growth driven by continued execution across the Company's key commercial portfolio, led by RECELL® and supported by increasing adoption of Cohealyx® and PermeaDerm®, and complemented by consistent international revenue o Gross profit margin of 81.9%, an increase of 70 basis points year-over-year, reflecting the growth of RECELL alongside the expansion of the Company’s other product portfolio • Operating expenses were $24.6 million, down 6% year-over-year, demonstrating continued operating discipline while supporting commercial growth • Net cash …
Open exhibit ↗Current Report · Items 2.02, 9.01 · 8-K
Avita Medical, Inc.
Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On August 6, 2026, the Company issued a press release announcing its financial results for the second quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.…
Company context
AVITA Medical® is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is RECELL®, approved by the FDA for the treatment of thermal burn and trauma wounds. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin™, offering an innovative solution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical also holds the exclusive rights to market, sell, and distribute Cohealyx®, an AVITA Medical-branded collagen-based dermal matrix, and the exclusive rights to manufacture, market, sell, and distribute PermeaDerm®, a biosynthetic wound matrix.